Proton magnetic resonance spectroscopy of fractionated plasma lipoproteins and reconstituted plasma from healthy subjects and patients with cancer

References

• Fosscl E T, Cart J M, McDonagh J. Detection of malignant tumors: water-suppressed proton nuclear magnetic resonance spectroscopy of plasma. N Engl J Med 1986; 315: 1369–76
   PubMed Web of Science ®Google Scholar
• Parl F F, Harris T M. Detection of malignant tumors by nuclear magnetic resonance spectroscopy of plasma. N Engl J Med 1987; 316: 1411–12
   PubMedGoogle Scholar
• Dowd T L, Kaplan B A, Gupta R K, Aisen P. Detection of malignant tumors: water-suppressed proton nuclear magnetic resonance spectroscopy of plasma. Magn Reson Med 1987; 5: 395–7
   PubMed Web of Science ®Google Scholar
• Wilding P, Senior M B, Inubushi T, Ludwick M L. Assessment of proton nuclear magnetic resonance spectroscopy for detection of malignancy. Clin Chem 1988; 34: 505–11
   PubMed Web of Science ®Google Scholar
• Peeling J., Sutherland G, Marat K, Tomchuk E, Bock E. 1H and 13C nuclear magnetic resonance studies of plasma from patients with primary intracranial neoplasms. J Neurosurg 1988; 68: 931–7
   PubMed Web of Science ®Google Scholar
• Buchthal S D, Hardy M A, Brown T R. Assessing the value of identifying the presence of malignant disease in human plasma by proton nuclear magnetic resonance spectroscopy. Am J Med 1988; 85: 528–32
   PubMed Web of Science ®Google Scholar
• Bell J D., Brown J CC, Norman R E, Sadler P J. Factors affecting 1H NMR spectra of blood plasma: cancer, diet and freezing. NMR Biomed 1988; 1: 90–4
   PubMedGoogle Scholar
• Chmurny G N, Hilton B D, Halverson D, McGregor G N, Klose J, Issaq H J, Muschik G M, Urba W J., Mellini M L, Costello R, Papadopoulos N M, Caporaso N, Smith I CP, Szuba M, Kroft T, Monck M, Saunders J K, Préfontaine M. An NMR blood test for cancer: a critical assessment. NMR Biomed 1988; 1: 136–50
   PubMedGoogle Scholar
• Holmes K T, Mackinnon W B, May G L, Wright L C, Dyne M, Tattersall M HN, Mountford C E, Sullivan D. Hyperlipidemia as a biochemical basis of magnetic resonance plasma test for cancer. NMR Biomed 1988; 1: 44–9
   PubMedGoogle Scholar
• Nabholtz J M, Rossignol A, Farnier M, Gambert P, Tremeaux J C, Friedman S, Guerrin J. Proton nuclear magnetic resonance spectroscopy of plasma lipoproteins in malignancy. Acta Oncol 1988; 27: 479–82
   PubMed Web of Science ®Google Scholar
• Berger S, Pflüger K H, Etzel W A, Fischer J. Detection of tumors with nuclear magnetic resonance spectroscopy of plasma. Eur J Cancer Clin Oncol 1989; 25: 535–43
   PubMedGoogle Scholar
• Engan T, Krane J, Klepp O, Kvinnsland S. Proton nuclear magnetic resonance spectroscopy of plasma from healthy subjects and patients with cancer. N Engl J Med 1990; 322: 949–53
   PubMed Web of Science ®Google Scholar
• Okunieff P, Zietman A, Kahn J, Singer S, Neuringer L J, Levine R A, Evans F E. Lack of efficacy of water-suppressed proton nuclear magnetic resonance spectroscopy of plasma for the detection of malignant tumors. N Engl J Med 1990; 322: 953–58
   PubMed Web of Science ®Google Scholar
• Schuhmacher J H, Conrad D, Manke H G, Clorius J H, Matys E R, Hauser H, Zuna I, Maier-Borst W, Hull W E. Investigations concerning the potential for using 1H NMR relaxometry of high-resolution spectroscopy of plasma as a screening test for malignant lung disease. Magn Reson Med 1990; 13: 103–32
   PubMed Web of Science ®Google Scholar
• Scher R L, Ropka M E, Neal D A, Berr S, Trouard T, Deutsch B, Cantrell R W, Levine P A. NMR spectroscopy evaluation of plasma ‘oncolipids’ in head and neck cancer. Otolaryngol Head Neck Surg 1990; 102: 34–40
   PubMed Web of Science ®Google Scholar
• Spiegel R J, Schaefer E J, Magrath I T, Edwards B K. Plasma lipid alterations in leukemia and lymphoma. Am J Med 1982; 72: 775–82
   PubMed Web of Science ®Google Scholar
• Nydegger U E, Butler R E. Serum lipoprotein levels in patients with cancer. Cancer Res 1972; 32: 1756–60
   PubMed Web of Science ®Google Scholar
• Alexopoulos C G, Blatsios B, Avgerinos A. Serum lipids and lipoprotein disorders in cancer patients. Cancer 1987; 60: 3065–70
   PubMed Web of Science ®Google Scholar
• Wieczorek A J, Rbyner C, Block L H. Isolation and characterization of an RNA-proteolipid complex associated with the malignant state in humans. Proc Natl Acad Sci USA 1985; 82: 3455–9
   PubMed Web of Science ®Google Scholar
• Barclay M, Skipski V P, Terebus-Kekish O., Greene E M, Kaufman R J, Stock C C. Effects of cancer upon high-density and other lipoproteins. Cancer Res 1970; 30: 2420–30
   PubMed Web of Science ®Google Scholar
• Wright L C, Sullivan D R, Muller M, Dyne M, Tattersall M HN, Mountford C E. Elevated apolipoprotein (a) levels in cancer patients. Int J Cancer 1989; 43: 241–4
   PubMed Web of Science ®Google Scholar
• Basu T K, Williams D C. Plasma and body lipids in patients with carcinoma of the breast. Oncology 1975; 31: 172–6
   PubMed Web of Science ®Google Scholar
• Mountford C E, May G L, Wright L C, Mackinnon W B, Dyne M, Holmes K T, vanHaaften-Day C, Tattersall M HN. Proteolipid identified by magnetic resonance spectroscopy in plasma of a patient with borderline ovarian tumour. Lancet 1987; i: 829–34
   Google Scholar
• Nicholson J K, Nicholson F. Proton spectroscopy of plasma and testing for malignancy. Lancet 1987; i: 280–1
   Google Scholar
• Fontanals-Ferrer N, Serrat-Serrat J, Sorribas-Vivas A, Gonzalez-Garcia C, Gonzalez-Sastre C, Gomez-Gerique J. Quick method of determining lipoproteins, including those of intermediate density, in serum. Clin Chem 1988; 34: 1753–7
   PubMed Web of Science ®Google Scholar
• Bell J D, Sadler P J, Macleod A F, Turner P R, LaVille A. 1H NMR studies of human blood plasma. FEBS Lett 1987; 219: 239–43
   PubMed Web of Science ®Google Scholar
• Mims M P, Morrisett J D, Mattioli C A, Gotto A M, Jr. Effect of triglyeeride levels on methyl and methylene envelope line widths in proton nuclear magnetic resonance spectroscopy of human plasma. N Engl J Med 1989; 320: 1452–7
   PubMed Web of Science ®Google Scholar
• Herring F G, Phillips P S, Pritchard P H. Proton magnetic resonance spectroscopy of plasma from patients with dyslipoproteinemia: identification of factors governing methyl and methylene proton linewidths. J Lipid Res 1989; 30: 521–8
   PubMed Web of Science ®Google Scholar
• Montes A, Walden C E, Knopp R H, Choung M, Chapman M B, Albers J J. Physiologic and supra-physiologic increases in lipoprotein lipids and apoproteins in late pregnancy and postpartum. Possible markers for the diagnosis of ‘prelipemia’. Arteriosclerosis 1984; 4: 407–17
   PubMedGoogle Scholar
• Evans F E, Levine R A., Okunieff P G. Effect of triglyeeride levels on methyl and methylene envelope line widths in proton nuclear magnetic resonance spectroscopy of human plasma. N Engl J Med 1989; 321: 1410–11
   Google Scholar
• Otvos J D, Jeyarajah E J, Hayes L W, Freedman D S, Janjan N A, Anderson T. Relationships between the proton nuclear magnetic resonance properties of plasma lipoproteins and cancer. Clin Chem 1991; 37: 369–76
   PubMed Web of Science ®Google Scholar
• Levy R I. The plasma lipoproteins: an overview. Trace components of plasma: isolation and clinical significance, G Jamieson, A. TJ. Greenwalt. Alan R. Liss, New York 1976; 25–42
   Google Scholar